Sign in to view content

Pooled Clinical Trial Safety Data of Neurotrophic Factorâ€“Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2

Paul S. Bernstein, MD, PhD

Video
Published 2024

Related

Mitochondria-Targeted Drug Elamipretide for Treatment of Vision Loss in Dry AMD With Noncentral Geographic Atrophy
Scott W. Cousins, MD
Annual Meeting Talks
2019
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025

Category: Hereditary Retinal Disease & Genetics

See more